MCUJF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 18:27):

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States...

Stats
Dagens volum	2 800.00
Gjennomsnittsvolum	1 274.00
Markedsverdi	7.72M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $0 ) 2024-05-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.57
ATR14	$0 (0.00%)

Medicure Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Medicure Inc. Økonomi

Annual	2023
Omsetning:	$21.69M
Bruttogevinst:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2023
Omsetning:	$21.69M
Bruttogevinst:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2022
Omsetning:	$23.07M
Bruttogevinst:	$16.08M (69.69 %)
EPS:	$0.130

FY	2021
Omsetning:	$21.74M
Bruttogevinst:	$12.71M (58.46 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Medicure Inc.

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.